Key Takeaways
- Gold prices saw a relief rally as US and Iranian negotiators reported progress toward a peace deal, though the metal remains down more than 20% since the start of the war.
- Federal Reserve Governor Austan Goolsbee defended his recent dissent, warning that inflation remains well above target and is currently moving in the "wrong direction."
- Pfizer (PFE) announced its Phase 3 trial for Sigvotatug Vedotin missed its overall survival goal in lung cancer patients, weighing on the healthcare sector.
- Iran and Oman confirmed a commitment to safe, toll-free passage through the Strait of Hormuz, easing global energy supply concerns.
- Fed Chair Warsh is officially scheduled to testify before the House Financial Services Committee on July 14 at 10:00 A.M. ET.
US-Iran Peace Progress Eases Energy Supply Fears
Negotiators from the United States and Iran have reported significant progress toward a peace deal, establishing a direct communication channel to prevent maritime escalations. Oman’s Foreign Minister noted that Iranian officials have reaffirmed their commitment to international law, specifically ensuring safe, toll-free passage for vessels through the Strait of Hormuz.
In tandem with these diplomatic shifts, Iran’s Central Bank Governor stated that the country’s remaining frozen assets will not be restricted to essential goods. Tehran clarified that it is not required to purchase U.S. agricultural products under the current framework and may use the funds for various non-sanctioned goods.
Gold Markets Caught Between Diplomacy and the Fed
Gold prices moved higher on Monday following the de-escalation news, yet the precious metal remains under significant long-term pressure. Market analysts point to a dual headwind of easing energy-supply fears and a persistently hawkish outlook from the Federal Reserve. Since the outbreak of the war, gold has depreciated by more than 20% as investors pivot toward higher-yielding assets.
Fed Officials Signal Continued Inflation Concerns
The Federal Reserve remains a focal point for markets as Governor Austan Goolsbee defended his decision to dissent against recent policy moves. Goolsbee emphasized that services inflation remains concerning and that the labor market's stability provides the Fed room to maintain restrictive rates. He noted that more evidence is required to prove that current price pressures are merely temporary.
Adding to the central bank's calendar, it was confirmed that Fed Chair Warsh will provide testimony to the House Financial Services Committee on July 14. Investors are bracing for further clarity on whether the Fed will maintain its aggressive stance given that inflation is still trending away from the 2% target.
Pfizer Clinical Trial Misses Primary Endpoint
In the healthcare sector, Pfizer (PFE) reported that its Phase 3 trial of Sigvotatug Vedotin failed to meet the primary goal of overall survival in patients with previously treated metastatic non-small cell lung cancer (NSCLC). While the drug showed stronger benefit trends in second-line patients and maintained a manageable safety profile, the failure to outperform the standard-of-care drug, Docetaxel, is a setback for the company’s oncology pipeline.
North Korea Asserts Nuclear Status
On the geopolitical front, North Korean leader Kim Jong Un stated that the nation will further assert its status and role as a nuclear power. According to reports from News1, this rhetoric signals a continued commitment to military expansion, potentially adding a layer of geopolitical risk to Asian markets as Pyongyang seeks to solidify its standing on the global stage.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.